Payment overview · 2025
General Payments
$607.34
10 reported records · 7 companies
Healthcare provider profile · identity verified
Cynthia Joyce Robinson, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · OSCEOLA, AR · NPI 1982230421
Verified facts
What the public records show
CMS Open Payments records show Cynthia Joyce Robinson, APRN received $607.34 in general payments during 2025 across 10 reported records.
Gilead Sciences, Inc. accounted for 24.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Kerendia.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Linzess by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Kerendia by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $148.12 | 24.4% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $137.48 | 22.6% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $133.08 | 21.9% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $124.86 | 20.6% | 1 | 2025 |
| Vertex Pharmaceuticals Incorporated | Unresolved — no canonical attribution shown | $25.76 | 4.2% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $23.29 | 3.8% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $14.75 | 2.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $607.34 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $137.48 | 2 | 2025 |
Source payment records
|
|||||
| Epclusa Normalized: epclusa |
Drug | Gilead Sciences, Inc. | $131.07 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $124.86 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | Vertex Pharmaceuticals Incorporated | $25.76 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $23.29 | 1 | 2025 |
Source payment records
|
|||||
| Biktarvy Normalized: biktarvy |
Drug | Gilead Sciences, Inc. | $17.05 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $15.87 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $14.75 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $14.75 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 82 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
35 | 16 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
82 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
66 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
106 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 295 | 125 |
| Losartan Potassium | Losartan Potassium | 203 | 81 |
| Atorvastatin Calcium | Atorvastatin Calcium | 191 | 83 |
| Famotidine | Famotidine | 182 | 83 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 112 | 49 |
| Trulicity | Dulaglutide | 106 | 22 |
| Gabapentin | Gabapentin | 93 | 40 |
| Jardiance | Empagliflozin | 82 | 26 |
| Montelukast Sodium | Montelukast Sodium | 73 | 48 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 68 | 44 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 67 | 33 |
| Mounjaro | Tirzepatide | 66 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 65 | 30 |
| Simvastatin | Simvastatin | 62 | 24 |
| Allopurinol | Allopurinol | 60 | 19 |
| Furosemide | Furosemide | 57 | 28 |
| Metformin Hcl | Metformin Hcl | 56 | 25 |
| Hydralazine Hcl | Hydralazine Hcl | 54 | 26 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 54 | 19 |
| Carvedilol | Carvedilol | 52 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 52 | 20 |
| Ozempic | Semaglutide | 52 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 49 | 14 |
| Metoprolol Succinate | Metoprolol Succinate | 48 | 24 |
| Tizanidine Hcl | Tizanidine Hcl | 46 | 30 |
| Fluticasone Propionate | Fluticasone Propionate | 45 | 29 |
| Doxycycline Hyclate | Doxycycline Hyclate | 43 | 39 |
| Methylprednisolone | Methylprednisolone | 41 | 38 |
| Levothyroxine Sodium | Levothyroxine Sodium | 38 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 37 | 16 |
| Glipizide | Glipizide | 35 | 14 |
| Linzess | Linaclotide | 35 | 16 |
| Farxiga | Dapagliflozin Propanediol | 34 | 17 |
| Potassium Chloride | Potassium Chloride | 34 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 34 | 14 |
| Spironolactone | Spironolactone | 33 | 12 |
| Ezetimibe | Ezetimibe | 32 | 17 |
| Trazodone Hcl | Trazodone Hcl | 32 | 14 |
| Lisinopril | Lisinopril | 31 | suppressed |
| Azithromycin | Azithromycin | 28 | 26 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 28 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 27 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 26 | 18 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 25 | suppressed |
| Atenolol | Atenolol | 24 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 24 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 24 | suppressed |
| Januvia | Sitagliptin Phosphate | 23 | 11 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 23 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 22 | 21 |
| Alendronate Sodium | Alendronate Sodium | 21 | 11 |
| Clonidine Hcl | Clonidine Hcl | 21 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Mupirocin | Mupirocin | 21 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 20 | suppressed |
| Eliquis | Apixaban | 20 | 11 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Glipizide Er | Glipizide | 19 | suppressed |
| Omeprazole | Omeprazole | 18 | suppressed |
| Fluconazole | Fluconazole | 17 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 17 | 12 |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Finasteride | Finasteride | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 15 |
| Clotrimazole | Clotrimazole | 15 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 15 | suppressed |
| Kerendia | Finerenone | 15 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 15 | 11 |
| Bumetanide | Bumetanide | 14 | 11 |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 13 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 13 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Phenobarbital | Phenobarbital | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Propafenone Hcl Er | Propafenone Hcl | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $607.34 · 10 records | Gilead Sciences, Inc. | Biktarvy, CAPVAXIVE, Epclusa, GARDASIL 9, GEMTESA, JARDIANCE, JOURNAVX, Kerendia, UBRELVY | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error